References
- Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 2011;183:1463-71
- Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100
- Döring G, Hoiby N; Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004;3:67-91
- Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30
- Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338:725-6
- De Boeck K, Breysem L. Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime. J Antimicrob Chemother 1998;41:407-9
- Murphy TD, Anbar RD, Lester LA, et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004;38:314-20
- Quittner AL, Buu A. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2002;33:269-76
- Dodd ME, Webb KA. Understanding non-compliance with treatment in adults with cystic fibrosis. J R Soc Med 2000;93(Suppl 38):2-8
- Geller DE. The science of aerosol delivery in cystic fibrosis. Pediatr Pulmonol 2009;43:S5-17
- Briesacher BA, Quittner AL, Saiman L, et al. Adherence with tobramycin inhalation solution and health care utilization. BMC Pulmonary Med 2011;11:5
- Geller D, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using Pulmosphere™ technology. J Aerosol Med Pulm Drug Deliv 2011;24:175-82
- Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis: the Eager trial. J Cyst Fibros 2011;10:54-61
- Knudson RJ, Lebowtiz MD, Holberg CJ, et al. Changes in the normal maximal expiratory flow–volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-34
- Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38
- Konstan MW, Geller DE, Minić P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatr Pulmonol 2011;46:230-8
- Box GEP, Hunter WG, Hunter JS. Statistics for Experimenters. New York: John Wiley & Sons, 1978
- Neuenschwander B, Capkun-Niggli G, Branson M, et al. Summarizing historical information on controls in clinical trials. Clin Trials 2010;7:5-18
- Chuchalin A, Csiszér E, Gyurkovics K, et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr Drugs 2007;9(Suppl 1):21-31
- Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-42
- Equi A, Balfour-Lynn IM, Bush A, et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-84
- Döring G, Elborn JS, Johannesson M, et al. Clinical trials in cystic fibrosis. J Cyst Fibros 2007;6:85-99